非肌层浸润性膀胱癌根治性膀胱切除术后复发与生存的预后因素:1032例多中心分析
该多中心回顾性队列纳入1032例病理NMIBC(pTis/pTa/pT1 N0 R0)行根治性膀胱切除术且未接受围手术期治疗的患者。中位随访45.2个月,淋巴血管侵犯(LVI,3.8%)独立关联无复发生存(HR 2.37)和癌症特异性生存(HR 2.59),病理分期与RFS无关,模型区分度 modest(C-index 0.59)。
要点
- LVI阳性是RFS和CSS的独立不良预后因素。
- 病理分期(pTis/pTa/pT1)对RFS无显著影响。
- 年龄预测总生存,LVI阳性者10年CSM更高。
核心结论
- 在病理NMIBC行RC的患者中,LVI识别出复发和CSM风险增加的小亚组,而病理分期附加信息有限。
- 这些发现支持LVI指导的监测和试验富集,但不能得出治疗推荐。
研究设计与样本
- 多中心回顾性队列,纳入1032例pTis/pTa/pT1 N0 R0疾病行RC(2000-2015)的患者,来自九个中心。
- 无患者接受围手术期治疗。
- 中位随访45.2个月。
主要发现
- LVI见于39例(3.8%),独立关联RFS(HR 2.37;95%CI 1.29-4.38;p=0.006)和CSS(HR 2.59;95%CI 1.31-5.10;p=0.006)。
- 病理分期与RFS无关(p=0.074)。
- 年龄预测OS(HR 1.06;p<0.001)。
- LVI阳性患者10年CSM更高(35.3% vs 13.7%;p=0.002)。
- 模型区分度 modest(C-index 0.59)。
临床怎么用
- LVI阳性患者可能需要更密切的监测。
- 病理分期在NMIBC行RC后的风险分层中附加价值有限。
- LVI可用于临床试验富集高危患者。
- 不能基于这些发现做出治疗推荐。
局限性
- 回顾性设计。
- LVI患病率低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Outcomes after radical cystectomy (RC) for non-muscle-invasive bladder cancer (NMIBC) are generally favorable, but a subset experiences recurrence and cancer-specific mortality (CSM). Tools to identify high-risk patients remain limited. This study aimed to identify predictors of recurrence and cancer-specific and overall mortality in pathological NMIBC treated with RC. DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective cohort of 1032 patients with pTis/pTa/pT1 N0 R0 disease who underwent RC (2000-2015) at nine centers. No patient received perioperative therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using Cox and competing-risks regression. Discrimination assessed by Harrell's C-index. RESULTS AND LIMITATIONS: Median follow-up 45.2 mo. Lymphovascular invasion (LVI), present in 39 patients (3.8%), was independently associated with RFS (hazard ratio [HR], 2.37; 95% confidence interval [CI], 1.29-4.38; p = 0.006) and CSS (HR, 2.59; 95% CI, 1.31-5.10; p = 0.006). Pathological stage was not associated with RFS (p = 0.074). Age predicted OS (HR 1.06; p < 0.001). LVI-positive patients had higher 10-yr CSM (35.3% vs 13.7%; p = 0.002). Discrimination was modest (C-index 0.59). Limitations include retrospective design and low LVI prevalence. CONCLUSIONS: In patients undergoing RC for pathological NMIBC, LVI identifies a small subgroup at increased risk of recurrence and CSM, while pathological stage adds little. These findings support LVI-guided surveillance and trial enrichment, but no treatment recommendations can be drawn.
引用
- Parizi MK, D'Andrea D, Pradere B, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non-muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients. Eur Urol Oncol. 2026. PMID: 42323256. doi:10.1016/j.euo.2026.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。